Skip to content
MS
Sign in
unreviewed

LDL receptor (LDLR)

0 reactions · 0 pathways

What it does, reaction by reaction

0 reactions

This enzyme appears only in the regulation table, with no catalysed step recorded.

What accelerates and inhibits it

Regulation is pathway-specific, so each context is listed separately

1 entries

Lipoprotein Metabolism (Exogenous and Endogenous Pathways: chylomicrons, VLDL, LDL, HDL)

Accelerated by

SREBP-2 when hepatocyte cholesterol is low; receptor recycling

Inhibited by

Intracellular cholesterol; PCSK9-mediated degradation

Hormonal control

Insulin can increase expression; statin-mediated cholesterol depletion strongly increases LDLR through SREBP-2

Recent literature

Refresh

Europe PMC · from cache · sorted by publication date

  1. 1
    Antibodies to watch in 2026.

    Crescioli S, Kaplon H, Chenoweth A, Hsu YS, Pinto K, Kapoor V, Reichert JM. · 2026-01-21

    cited 11× open access unreviewed
  2. 2
    Nitazoxanide reduces atherosclerosis by decreasing polarization of macrophages to proinflammatory M1 phenotype via inhibition of NF-κB pathway.

    Czepiel K, Kuś K, Skórkowska A, Wiśniewska A, Kuśnierz-Cabala B, Kiepura A, Jelito D, Suski M, Kostogrys RB, … · 2026-05-28

    unreviewed
  3. 3
    Early atherogenesis: In search of etiology.

    Brown PA. · 2026-05-07

    open access unreviewed
  4. 4
    High-fat diet differentially alters hippocampal lipidomic and metabolomic profiles and cognition-related behavior in wild-type and LDL receptor-deficient mice.

    Liao W, Ren J, Rong Y, Xie C, Yang X. · 2026-07-23

    unreviewed
  5. 5
    Experimental atherosclerosis models in small animals (Review).

    Balkar ME, Parlakpinar H. · 2026-05-18

    open access unreviewed
  6. 6
    Genetic Influence on LDL-Cholesterol Levels: Role of Polygenic Risk Scores and Lp(a) Beyond Monogenic Hypercholesterolemia

    Ferrandino M, Cerrato Y, Iannuzzo G, Calcaterra I, Di Minno M, Fortunato G, Di Taranto M. · 2026-06-01

    open access unreviewed
  7. 7
    Fluoxetine disrupts cholesterol metabolism in endothelial cells via SREBP2 activation.

    Oliveira F, Papa C, Hagemann T, Schipper R, Geier F, Röxe T, Zulfqar F, Prönnecke C, Schmidt L, Stryhanyuk H,… · 2026-06-23

    open access unreviewed
  8. 8
    Review: natural compounds as PCSK9 inhibitors for antiviral therapy.

    Kareem RA, Sameer HN, Athab ZH, Adil M, Yaseen A, Allela OQB. · 2026-06-22

    unreviewed
  9. 9
    The lysophosphatidylcholine-HIF-1α axis enhances apolipoprotein E sialylation and promotes electronegative LDL accumulation.

    Chan HC, Chan HC, Wang LF, Chan ML, Huang WC, Bender D, Ko YM, Yu ML, Ke GM, Chou MC, Liu CK, Ke LY. · 2026-06-05

    open access unreviewed
  10. 10
    Context-Dependent Effects of Apolipoprotein A2 on Lipid Metabolism and Atherogenesis.

    Zvintzou E, Fenyo IM, Ionita R, Kakafoni G, Dumitrescu M, Alemi M, Daraban BS, Marinos K, Gafencu AV, Kypreos… · 2026-06-01

    open access unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.